Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis

Blood

Volumn 104, Issue 5, 2004, Pages 1435-1441

  Zaza, Gianluigi ^b   Yang, Wenjian ^b   Kager, Leo ^b   Cheok, Meyling ^b   Downing, James ^b   Pui, Ching Hon ^b   Cheng, Cheng ^b   Relling, Mary V ^b   Evans, William E ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; CARBOXYLASE; FRAGILE HISTIDINE TRIAD PROTEIN; GENE PRODUCT; INOSINATE DEHYDROGENASE; MERCAPTOPURINE; METHOTREXATE; NONMETASTATIC PROTEIN; PHOSPHORIBOSYL AMINOIMIDAZOLE CARBOXYLASE; PURINE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; B LYMPHOBLAST; CANCER CLASSIFICATION; CELL LINEAGE; CHILD; CONTROLLED STUDY; DRUG TARGETING; FUSION GENE; GART GENE; GENE; GENE EXPRESSION; GENE TRANSLOCATION; HPRT GENE; HUMAN; HUMAN CELL; IMPDH GENE; LYMPHOBLAST; MAJOR CLINICAL STUDY; PAICS GENE; PRIORITY JOURNAL; PURINE METABOLISM; PURINE SYNTHESIS; T LYMPHOBLAST; TEL AML1 GENE; WESTERN BLOTTING;

EID: 4444366020     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-12-4306     Document Type: Article

References (52)

1. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615.
2. Batova A, Diccianni MB, Nobori T, et al. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. Blood. 1996;88:3083-3090.
3. Yamaoka T, Yano M, Kondo M, et al. Feedback inhibition of amidophosphoribosyltransferase regulates the rate of cell growth via purine nucleotide, DNA, and protein syntheses. J Biol Chem. 2001;276:21285-21291.
4. Lehninger AL, Nelson DL, Cox MM. Principles of Biochemistry. 2nd ed. New York, NY: Worth Publishers; 1993.
5. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1:133-143.
6. Cheok MH, Yang W, Pui CH, et al. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells. Nat Genet. 2003;34:85-90.
7. Dervieux T, Brenner TL, Hon YY, et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood. 2002;100:1240-1247.
8. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest. 1996;97:73-80.
9. Masson E, Synold TW, Relling MV, et al. Allopurinol inhibits de novo purine synthesis in lymphoblasts of children with acute lymphoblastic leukemia. Leukemia. 1996;10:56-60.
10. Ross ME, Zhou X, Song G, et al. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood. 2003;102:2951-2959.
11. Lipshutz RJ, Fodor SP, Gingeras TR, Lockhart DJ. High density synthetic oligonucleotide arrays. Nat Genet. 1999;21:20-24.
12. Hattori M, Okuno Y, Goto S, Kanehisa M. Development of a chemical structure comparison method for integrated analysis of chemical and genomic information in the metabolic pathways. J Am Chem Soc. 2003;125:11853-11865.
13. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science. 1999;286:531-537.
14. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia-current status and future perspectives. Lancet Oncol. 2001;2:597-607.
15. Scholar EM, Calabresi P. Identification of the enzymatic pathways of nucleotide metabolism in human lymphocytes and leukemia cells. Cancer Res. 1973;33:94-103.
16. Piga A, Sylwestrowicz T, Ganeshaguru K, et al. Nucleoside incorporation into DNA and RNA in acute leukaemia: differences between the various leukaemia sub-types. Br J Haematol. 1982;52:195-204.
17. van Laarhoven JP, de Bruyn CH. Purine metabolism in relation to leukemia and lymphoid cell differentiation. Leuk Res. 1983;7:451-480.
18. Poplack DG, Blatt J, Reaman G. Purine pathway enzyme abnormalities in acute lymphoblastic leukemia. Cancer Res. 1981;41:4821-4823.
19. Rubnitz JE, Behm FG, Pui CH, et al. Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII. Leukemia. 1997;1t:1201-1206.
20. Hebert J, Cayuela JM, Berkeley J, Sigaux F. Candidate tumor-suppressor genes MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous deletions in primary cells from T- but not from B-cell lineage acute lymphoblastic leukemias. Blood. 1994;84:4038-4044.
21. Magalhaes IQ, Pombo-de-Oliveira MS, Bennett CA, et al. TEL-AML1 fusion gene frequency in paediatric acute lymphoblastic leukaemia in Brazil. Br J Haematol. 2000;111:204-207.
22. Shurtleff SA, Buijs A, Behm FG, et al. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995;9:1985-1989.
23. Jamil A, Theil KS, Kahwash S, Ruymann FB, Klopfenstein KJ. TEL/AML-1 fusion gene. its frequency and prognostic significance in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet. 2000;122:73-78.
24. Borkhardt A, Cazzaniga G, Viehmann S, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Associazione Italiana Ematologia Oncologia Pediatdca and the Berlin-Frankfurt-Munster Study Group. Blood. 1997;90:571-577.
25. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-330.
26. Romana SP, Mauchauffe M, Le Coniat M, et al. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood. 1995;85:3662-3670.
27. Wang LC, Swat W, Fujiwara Y, et al. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow. Genes Dev. 1998;12:2392-2402.
28. Wiemels JL, Cazzaniga G, Daniotti M, et al. Prenatal origin of acute lymphoblastic leukaemia in children. Lancet. 1999;354:1499-1503.
29. Greaves M. Molecular genetics, natural history and the demise of childhood leukaemia. Eur J Cancer. 1999;35:1941-1953.
30. Rubnitz JE, Downing JR, Pui CH, et al. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol. 1997;15:1150-1157.
31. Loh ML, Silverman LB, Young ML, et al. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. Blood. 1998;92:4792-4797.
32. Seeger K, Viehmann S, Buchwald D, et al. Treatment response and residual-disease monitoring in initial and relapsed TEL-AML1 positive childhood ALL. Leukemia. 2001;15:280-282.
33. Harbott J, Viehmann S, BorkhardtA, Henze G, Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood. 1997;90:4933-4937.
34. Choi SW, Mason JB. Folate and carcinogenesis: an integrated scheme. J Nutr. 2000;130:129-132.
35. McLean TW, Ringold S, Neuberg D, et al. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996;88:4252-4258.
36. Luan X, Ramesh KH, Cannizzaro LA. FHIT gene transcript alterations occur frequently in myeloproliferative and myelodysplastic diseases. Cytogenet Cell Genet. 1998;81:183-188.
37. Lin PM, Liu TC, Chang JG, Chen TP, Lin SF. Aberrant FHIT transcripts in acute myeloid leukaemia. BrJ Haematol. 1997;99:612-617.
38. Pekarsky Y, DruckT, Cotticelli MG, et al. The murine Fhit locus: isolation, characterization, and expression in normal and tumor cells. Cancer Res. 1998;58:3401-3408.
39. Inoue H, Ishii H, Alder H, et al. Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc Natl Acad Sci U S A. 1997;94:14584-14589.
40. Stahl JA, Leone A, Rosengard AM, et al. Identification of a second human nm23 gene, nm23-H2. Cancer Res. 1991;51:445-449.
41. Gilles AM, Presecan E, Vonica A, Lascu L. Nucleoside diphosphate kinase from human erythrocytes. Structural characterization of the two polypeptide chains responsible for heterogeneity of the hexameric enzyme. J Biol Chem. 1991;266:8784-8789.
42. MacDonald NJ, de la Rosa A, Steeg PS. The potential roles of nm23 in cancer metastasis and cellular differentiation. Eur J Cancer. 1995;31A:1096-1100.
43. Bevilacqua G, Sobel ME, Liotta LA, Steeg PS. Association of low nm23 RNA levels in human primary infiltrating ductal breast carcinomas with lymph node involvement and other histopathological indicators of high metastatic potential. Cancer Res. 1989;49:5185-5190.
44. Nakayama T, Ohtsuru A, Nakao K, et al. Expression in human hepatocellular carcinoma of nucleoside diphosphate kinase, a homologue of the nm23 gene product. J Natl Cancer Inst. 1992;84:1349-1354.
45. Mandai M, Konishi I, Koshiyama M, et al. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression. Cancer Res. 1994;54:1825-1830.
46. Florenes VA, Aamdal S, Myklebost O, et al. Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res. 1992;52:6088-6091.
47. Aryee DN, Simonitsch I, Mosberger I, et al. Variability of nm23-H1/NDPK-A expression in human lymphomas and its relation to tumour aggressiveness. Br J Cancer. 1996;74:1693-1698.
48. Yokoyama A, Okabe-Kado J, Wakimoto N, et al. Evaluation by multivariate analysis of the differentiation inhibitory factor nm23 as a prognostic factor in acute myelogenous leukemia and application to other hematologic malignancies. Blood. 1998;91:1845-1851.
49. Jackson RC, Weber G, Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature. 1975;256:331-333.
50. Itoh O, Kuroiwa S, Atsumi S, et al. Induction by the guanosine analogue oxanosine of reversion toward the normal phenotype of K-ras-transformed rat kidney cells. Cancer Res. 1989;49:996-1000.
51. Kiguchi K, Collart FR, Henning-Chubb C, Huberman E. Cell differentiation and altered IMP dehydrogenase expression induced in human T-lymphoblastoid leukemia cells by mycophenolic acid and tiazofurin. Exp Cell Res. 1990;187:47-53.
52. Pieters R, Huismans DR, Loonen AH, et al. Hypoxanthine-guanine phosphoribosyl-transferase in childhood leukemia: relation with immunophenotype, in vitro drug resistance and clinical prognosis. Int J Cancer. 1992;51:213-217.